596

David Gagnon, Gabriel Fontaine, Kathryn Smith, Russell Miller, Richard Riker, Patricia Lerwick, Kristen Sihler, Gilles Fraser
  • Critical Care Medicine, December 2015, Wolters Kluwer Health
  • DOI: 10.1097/01.ccm.0000474424.95007.e4

What is it about?

Valproic acid (VPA) is an emerging option for behavioral control in critically ill patients. The purpose of this study was to describe its safety and efficacy for this indication. VPA therapy was associated with a reduction in agitation incidence and opioid utilization. Further studies in this patient population are warranted.

Read Publication

http://dx.doi.org/10.1097/01.ccm.0000474424.95007.e4

The following have contributed to this page: Gabriel V Fontaine